PMID- 26136324
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20150703
IS  - 0301-2603 (Print)
IS  - 0301-2603 (Linking)
VI  - 43
IP  - 7
DP  - 2015 Jul
TI  - [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade 
      Gliomas].
PG  - 603-10
LID - 10.11477/mf.1436203084 [doi]
AB  - BACKGROUND: In Japan, patients with malignant glioma have been treated with BCNU 
      wafers (Gliadel(R)) since January 2013. Several adverse events(AEs)associated with 
      implantation of BCNU wafers, including cerebral edema or cyst formation, are 
      recognized. Here, we report a retrospective review of the experience with 
      implantation of BCNU wafers in our institutions and our findings regarding the 
      risk factors for the AEs. METHODS: We reviewed the records of patients with 
      malignant glioma who were implanted with BCNU wafers between April 2013 and 
      September 2014. Their AEs were examined clinically and radiologically and 
      evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) 
      grading. For investigating the association between risk factors and incidence of 
      AEs, histological diagnosis, extent of resection, and period of BCNU wafers 
      implantation surgery were selected as possible risk factors. RESULTS: Twenty-one 
      patients were included in this investigation. There were no associations among 
      incidence of AEs and histological diagnosis or extent of tumor resection. 
      However, regarding the period of BCNU wafers implantation, additional resection 
      for newly diagnosed tumors and resection for recurrent tumors tended to increase 
      the rate and severity of AEs, especially cerebral edema, compared to primary 
      resection. CONCLUSION: In cases of BCNU wafers implantation, the incidence and 
      degree of AEs might increase if additional resection for newly diagnosed tumors 
      or resection for recurrent tumors is performed. Our investigation revealed that 
      AEs associated with implantation of BCNU wafers tend to occur in the repeated 
      glioma surgery.
FAU - Yoshida, Michiharu
AU  - Yoshida M
AD  - Department of Neurosurgery, Graduate School of Medicine, Hokkaido University.
FAU - Yamaguchi, Shigeru
AU  - Yamaguchi S
FAU - Ishi, Yukitomo
AU  - Ishi Y
FAU - Endo, Shogo
AU  - Endo S
FAU - Motegi, Hiroaki
AU  - Motegi H
FAU - Kobayashi, Hiroyuki
AU  - Kobayashi H
FAU - Asaoka, Katsuyuki
AU  - Asaoka K
FAU - Kamoshima, Yuuta
AU  - Kamoshima Y
FAU - Terasaka, Shunsuke
AU  - Terasaka S
FAU - Houkin, Kiyohiro
AU  - Houkin K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - No Shinkei Geka
JT  - No shinkei geka. Neurological surgery
JID - 0377015
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Decanoic Acids)
RN  - 0 (Polyesters)
RN  - 0 (carmustine, poliferprosan 20 drug combination)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Alkylating/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/pathology/surgery
MH  - Carmustine/administration & dosage/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Decanoic Acids/administration & dosage/adverse effects/*therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Glioma/*drug therapy/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Polyesters/administration & dosage/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2015/07/03 06:00
MHDA- 2015/10/27 06:00
CRDT- 2015/07/03 06:00
PHST- 2015/07/03 06:00 [entrez]
PHST- 2015/07/03 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 1436203084 [pii]
AID - 10.11477/mf.1436203084 [doi]
PST - ppublish
SO  - No Shinkei Geka. 2015 Jul;43(7):603-10. doi: 10.11477/mf.1436203084.